Read Part 2 of Precision’s Take on the Changing View of Biosimilars
In part 2 of their Guest Commentary series, Precision’s Todd Edgar, Alex Grosvenor, and Kellie Rademacher highlight the takeaways of the NOR-SWITCH trial and how the EU’s view of biosimilars as therapeutic alternatives is influencing US policy. (more…)
Don’t Miss Precision Xtract and MM&M’s Free Live Webinar & Protect Your Innovation From Unfair Value Assessment
Register today for our upcoming free live webinar Defend Your Value: Syncing Evidence and Access Strategies to Prepare for US Value Assessments on Wednesday, April 18, at 1:00 pm ET. (more…)
Maclean and Jansen Advocate for Open-Source Modeling in Pharmaceutical Executive
Precision’s Ross Maclean and Jeroen Jansen encourage biopharma and medical device industries to embrace the developments around value assessment and to take a leading role in improving the transparency of cost-effectiveness evaluations. (more…)
Schafer and Hennessey on the Importance of Value Among Pharma Marketers
In a feature in Pharma Live, Precision’s Jeremy Schafer and Maureen Hennessy predict that the projected growth in healthcare spend is creating an inevitable marketplace shift from volume to value. (more…)
Shafrin Quoted on the Use of Real-World Evidence
Precision’s Jason Shafrin comments in PMLive on the importance of real-world evidence and the benefits of electronic medical records in generating evidence. (more…)